Rheumatoid Arthritis

New report assesses the quality of rheumatic disease care across all 50 states and calls for improvements that address access to affordable care.

Top news of the week from Specialty Pharmacy Times.

New drug could serve as a potential treatment option for patients who have shown an inadequate response to conventional disease-modifying drugs.

The rate of disease progression in patients with rheumatoid arthritis (RA) can be associated with a poor prognosis in patients.

Childhood exposure to secondhand smoke may heighten the risk of developing rheumatoid arthritis (RA) later in life, even in non-smokers, according to new research.

Exposure to secondhand smoke in childhood can lead to greater risk of rheumatoid arthritis later in life, even in non-smoking adults.

A symposium presented at the Asembia Specialty Pharmacy Summit 2018 provided pharmacists a review of guideline-based RA management strategies, along with recent trial data on new and emerging agents.

In response to the Trump Administration’s drug pricing blueprint, the American College of Rheumatology issued a set of policy principles on drug prices and access to rheumatology treatment.

Upadacitinib is currently being tested in phase 3 trials of rheumatoid arthritis, psoriatic arthritis and Crohn’s disease, and is being investigated to treat ulcerative colitis, ankylosing spondylitis, atopic dermatitis and giant cell arteritis.

Baricitinib is indicated as a monotherapy or in combination with methotrexate or other disease-modifying antirheumatic drugs for adults with moderately-to-severely active rheumatoid arthritis.

The FDA has approved baricitinib (Olumiant), a once-daily oral drug for adults with moderately-to-severely active rheumatoid arthritis.

The 2019 Benefit and Payment Parameters final rule allows states to select their own Essential Health Benefits benchmark plans.

Top news of the day from across the health care landscape.

Ron Lanton III, Esq, President, True North Political Solutions, makes predictions about how dealings with biosimilars may change in 2018.

Upadacitinib, an oral agent designed to selectively inhibit JAK1, is being studied as a once-daily therapy in rheumatoid arthritis.

Upadacitinib met primary endpoints of ACR20 and clinical remission versus placebo in treatment of moderate to severe rheumatoid arthritis.

Genetic sequencing of joint biopsies may identify which patients with rheumatoid arthritis may respond to therapy.

With the introduction of biologics such as Humira, Enbrel, and Remicade to treat RA, prescription costs have steadily increased.

Targeting an energy-related molecule could prevent the onset of autoimmune diseases.

Less serious adverse events remain a concern for patients treated for chronic diseases.

An immunomodulatory cytokine interacts with its receptors differently than other cytokines.

Investigational JAK1-selective inhibitor may reduce the symptoms of atopic dermatitis.

Treatment with upadacitinib resulted in reduced disease activity and clinical remission in patients with rheumatoid arthritis.

A look at the most popular videos on The American Journal of Pharmacy Benefits over the past year.

A review of the most popular video interviews on Specialty Pharmacy Times.